完善我国药品专利强制许可制度的思考

发布时间：2019-04-23 20:49

【摘要】：由于药品对于公共健康的特殊意义，它的专利保护已经成为敏感而又重要的话题。《与贸易有关的知识产权协定》（TRIPS协定）中，就已经规定了关于药品的专利保护和强制许可问题，我国也在2009年10月1日正式生效的《专利法》以及2010年1月9日颁布的《专利法实施细则》中做出了关于专利强制许可制度的规定，期望以此来保护我国公民的公共健康。本文重点从以下几个章节来讨论药品专利强制许可制度在我国应用的相关问题：第一章从公共健康来看药品的专利问题，之所以要实施药品专利强制许可，一个重要的原因就在于药品专利保护和公共健康的冲突，当今世界的公共健康危机已经愈来愈频繁，导致世界各国的公共健康状态都存在问题，我国公共健康现状也不容乐观。所以本章就从公共健康角度来研究药品专利问题，引出药品专利强制许可制度对保护公共健康的影响。第二章是对我国药品专利强制许可制度的概述，介绍了我国药品专利强制许可立法的历史沿革，并着重分析了近几年对该制度在立法方面的主要修改，阐述了我国药品专利强制许可零实施的现状，，并分析原因。最后简述了药品专利强制许可的相关概念以及药品专利强制许可的实施意义。第三章是本文亮点，主要介绍TRIPS协议中有关药品专利强制许可制度的一些规定，肯定了TRIPS协议在该问题中的发展，并指出TRIPS协议中规定的不足。第四章展开了对我国的药品专利强制许可制度的分析，本章为本文重点，从我国公共健康及药品可及性现状入手，指出了我国药品专利强制许可制度的不足。并从主体、程序、救济等方面提出建议。
[Abstract]:Because of its special significance for public health, patent protection of medicines has become a sensitive and important topic. In the Agreement on Trade-related aspects of intellectual property Rights (TRIPS Agreement), There have been provisions on patent protection and compulsory licensing of medicines, In order to protect the public health of our citizens, China also made provisions on the compulsory patent licensing system in the Patent Law, which entered into force on October 1, 2009 and the implementing rules of the Patent Law, which was promulgated on January 9, 2010, in order to protect the public health of our citizens. This article focuses on the following chapters to discuss the application of the compulsory licensing system of pharmaceutical patents in China: chapter one: from the perspective of public health, the reason why the compulsory licensing of pharmaceutical patents should be implemented is that the compulsory licensing of pharmaceutical patents should be implemented in the light of public health. One of the important reasons lies in the conflict between patent protection and public health. The public health crisis in the world has become more and more frequent, which leads to problems in the public health status of all countries in the world, and the present situation of public health in our country is not optimistic. Therefore, this chapter studies the problem of drug patent from the perspective of public health, and leads to the influence of compulsory licensing system of drug patent on the protection of public health. The second chapter is an overview of the compulsory licensing system of pharmaceutical patents in China, introduces the historical evolution of the legislation of compulsory licensing of pharmaceutical patents in China, and emphatically analyzes the major legislative amendments to the system in recent years. This paper expounds the current situation of zero implementation of compulsory licensing of pharmaceutical patents in China, and analyzes the reasons. Finally, the related concepts of compulsory licensing of pharmaceutical patents and the implementation significance of compulsory licensing of pharmaceutical patents are briefly described. The third chapter is the highlight of this paper, which mainly introduces some regulations of the compulsory licensing system of pharmaceutical patents in the TRIPS agreement, affirms the development of the TRIPS agreement in this issue, and points out the shortcomings of the TRIPS agreement. The fourth chapter analyzes the compulsory licensing system of pharmaceutical patent in our country. This chapter is the focus of this paper, starting with the current situation of public health and drug accessibility in our country, it points out the shortcomings of the compulsory licensing system of pharmaceutical patent in our country. And from the main body, procedures, relief and other aspects of the recommendations.
【学位授予单位】：新疆财经大学
【学位级别】：硕士
【学位授予年份】：2012
【分类号】：D997.1

【相似文献】